Patents Issued in September 4, 2018
-
Patent number: 10064865Abstract: The present invention relates to a composition and health functional food for inhibiting apoptosis of cranial nerve cells, and to a method for inhibiting apoptosis, wherein the composition and health functional food comprising a phosphodiesterase type 5 active inhibitor. According to the present invention, the PDE5 inhibitor exhibits a protective effect on nerve cells by inhibiting apoptosis of cranial nerve cells. Thus, the present invention can be effectively used to prevent, alleviate, and treat cranial nerve disease.Type: GrantFiled: July 28, 2017Date of Patent: September 4, 2018Assignees: ARIBIO CO., LTD., SK CHEMICALS CO., LTD.Inventors: Myung Hwa Kim, Jae Jun Choung, Sae Kwang Ku
-
Patent number: 10064866Abstract: This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3K?.Type: GrantFiled: April 7, 2015Date of Patent: September 4, 2018Assignee: Incyte CorporationInventors: Peggy A. Scherle, Xuesong Liu
-
Patent number: 10064867Abstract: The disclosure relates to Compounds of Formula (1): and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof, and methods to treat or prevent a condition, such as cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 9, 2016Date of Patent: September 4, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Tony Taldone, Gabriela Chiosis
-
Patent number: 10064868Abstract: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.Type: GrantFiled: June 3, 2015Date of Patent: September 4, 2018Assignee: MEI PHARMA, INC.Inventors: S. David Brown, David J. Matthews
-
Patent number: 10064869Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.Type: GrantFiled: June 4, 2015Date of Patent: September 4, 2018Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNINGInventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier, Roland Julius Yu Fiskesund
-
Patent number: 10064870Abstract: The present disclosure relates generally to sol-gel polymer composites that comprise chitosan, a hydrophilic polymer, a gelation agent, and optional additional ingredients in a suitable medium. Advantageously, the sol-gel polymer composite can form a durable seal or strong solid in response to one or more physiological stimulus. The disclosure further relates to medical and veterinary uses of the composite, particularly, methods and delivery systems for reducing or preventing the incidence of a mammary disorder in a dairy animal. More particularly, the disclosure includes methods and sol-gel polymer composite compositions for creating a physical barrier on the teat surface or in the teat canal or cistern of a non-human animal for prophylactic treatment of mammary disorders such as mastitis wherein the sol-gel polymer creates a seal in response to one or more physiological stimulus.Type: GrantFiled: November 2, 2016Date of Patent: September 4, 2018Assignee: Zoetis Services LLCInventors: Sumitra Rajagopalan, Wilms Baille, Piotr Kujawa, Christopher A. Zook, Rebecca R. Quesnell, Dennis L. Huczek, Stephen L. Secreast, Laibin Luo, Tammy A. Sanders
-
Patent number: 10064871Abstract: A method of treating a skin disorder (e.g., an inflammatory or neoplastic skin disorder) in a subject in need thereof is carried out by administering (e.g., topically administering) the subject an active agent in a treatment effective amount. The active agent may be a compound of Formula I: wherein: each R is independently selected substituted or unsubstituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; each A is an independently selected hydrogen, an electron-withdrawing group, or electron donating group; M is a metal; and Z? is a counterion; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 21, 2015Date of Patent: September 4, 2018Assignee: BioMimetix JV, LLCInventors: James D. Crapo, Kimberly C. Stone
-
Patent number: 10064872Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.Type: GrantFiled: July 17, 2017Date of Patent: September 4, 2018Assignee: Allergan, Inc.Inventors: James Chang, Patrick Hughes, Chin-Ming Chang
-
Patent number: 10064873Abstract: The present invention relates to compounds characterized by having a structure according to the following Formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.Type: GrantFiled: March 21, 2017Date of Patent: September 4, 2018Assignee: GLAXOSMITHKLINE LLCInventor: Brian Alvin Johns
-
Patent number: 10064874Abstract: The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-memopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.Type: GrantFiled: October 22, 2015Date of Patent: September 4, 2018Assignee: HAVAH THERAPEUTICS PTY LTD.Inventor: Stephen Nigel Birrell
-
Patent number: 10064875Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.Type: GrantFiled: March 22, 2018Date of Patent: September 4, 2018Assignee: PROMIUS PHARMA LLCInventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
-
Patent number: 10064876Abstract: Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject.Type: GrantFiled: July 25, 2016Date of Patent: September 4, 2018Assignee: Vanderbilt UniversityInventors: Aurelio Galli, Heinrich J. G. Matthies, Naji N. Abumrad, India A. Reddy, Charles Robb Flynn, Kevin Erreger
-
Patent number: 10064877Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention.Type: GrantFiled: December 5, 2016Date of Patent: September 4, 2018Assignee: THERAPEUTIC RESEARCH, LLCInventor: Jay Pravda
-
Patent number: 10064878Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.Type: GrantFiled: December 5, 2016Date of Patent: September 4, 2018Assignee: COSMO TECHNOLOGIES LTD.Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
-
Patent number: 10064879Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH2—; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).Type: GrantFiled: April 24, 2017Date of Patent: September 4, 2018Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Nobuaki Ito, Hirofumi Sasaki, Kuninori Tai, Tomoichi Shinohara
-
Patent number: 10064880Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.Type: GrantFiled: March 15, 2018Date of Patent: September 4, 2018Assignee: BlinkBio, Inc.Inventors: Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
-
Patent number: 10064881Abstract: Provided is an all natural composition including naturally-obtained plant extracts.Type: GrantFiled: December 8, 2011Date of Patent: September 4, 2018Assignees: Y&B Mother's Choice Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Tova Silberstein, Rachel Lutz, Shlomo Magdassi, Barak Tzadok
-
Patent number: 10064882Abstract: Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period.Type: GrantFiled: June 30, 2017Date of Patent: September 4, 2018Assignee: INSMED INCORPORATEDInventor: Renu Gupta
-
Patent number: 10064883Abstract: The present invention relates to a pharmaceutical composition including Lipiodol and a molecule with anti-tumor activity and secondarily a hydroxyethyl starch. The present invention also relates to the use of the compositions according to the invention for treating cancer. According to one embodiment, the pharmaceutical composition according to the invention has between 0.004% and 0.2% by weight of idarubicin, between 0.38% and 2.25% by weight of hydroxyethyl starch and secondarily between 60% and 68% by weight of Lipiodol, and water for injection (or even physiological saline) in a quantity sufficient (q.s.) for 100%.Type: GrantFiled: July 5, 2013Date of Patent: September 4, 2018Assignee: GUERBETInventors: Boris Guiu, Mathieu Boulin, Jean-Pierre Cercueil
-
Patent number: 10064884Abstract: Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.Type: GrantFiled: July 29, 2016Date of Patent: September 4, 2018Assignee: Curology, Inc.Inventor: David Lortscher
-
Patent number: 10064885Abstract: A novel pathway in cancer cell metabolism is identified. Targeting of any gene, protein, or enzyme that modulates activity or flux through this pathway, including, but not limited to IDH1, isocitrate dehydrogenase 2 (IDH2), aconitase 1 (ACO1), aconitase 2 (ACO2), glutaminase (GLS), glutamate dehydrogenase (GDH) and transaminase, provides effective means of inhibiting tumor growth.Type: GrantFiled: July 8, 2011Date of Patent: September 4, 2018Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Gregory Stephanopoulos, Christian M. Metallo, Joanne K. Kelleher, Othon Iliopoulos, Paulo Alexandre da Costa Gameiro Guerreiro
-
Patent number: 10064886Abstract: Disclosed are compositions comprising synergic combinations of xyloglucans and plant or animal proteins, which are useful in the treatment of intestinal disorders.Type: GrantFiled: May 17, 2017Date of Patent: September 4, 2018Assignee: NOVINTETHICAL PHARMA SAInventors: Miguel Angel Alonso Cohen, Michele Giuseppe Di Schiena, Marco Di Fulvio
-
Patent number: 10064887Abstract: The present invention describes and claims pharmaceutical compositions in gel form for use in the treatment of intervertebral disc degeneration, in particular the forms of dehydration and emptying of the nucleus pulposus known as “black disc disease”. These compositions comprise a hyaluronic acid derivative which forms hydrogels with precise rheological characteristics that make it ideal for filling the nucleus pulposus.Type: GrantFiled: April 23, 2014Date of Patent: September 4, 2018Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Nicola Giordan, Pierangelo Bellato
-
Patent number: 10064888Abstract: This invention provides (a) nanoparticle made of: sugar-beet pectin; and a bioactive compound (such as a nutraceutical or a drug) bound to sugar-beet pectin. The invention further provides foods, beverages, including clear ones, or pharmaceutical preparations, which are supplemented with the nanoparticles made of: sugar-beet pectin; and a hydrophobic bioactive compound bound to sugar-beet pectin. The process of making the nanoparticles of the invention, and methods for supplementing foods or beverages or pharmaceutical preparations with bioactive compounds via the nanoparticles of the invention are also provided.Type: GrantFiled: March 12, 2018Date of Patent: September 4, 2018Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.Inventor: Yoav Livney
-
Patent number: 10064889Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.Type: GrantFiled: March 23, 2016Date of Patent: September 4, 2018Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.Inventors: Xiaozheng Shu, Weiping Zhong, Yunyun Wang, Meixia Yu
-
Patent number: 10064890Abstract: Provided are methods for treating calcium malabsorption and conditions associated with calcium malabsorption, employing the administration of a composition containing stable amorphous calcium carbonate. Further provided are methods for increasing bone mineral density in a bone metabolism associated disorders, diseases or conditions, employing the administration of said composition in combination with a bone resorption inhibitor.Type: GrantFiled: December 13, 2012Date of Patent: September 4, 2018Assignee: AMORPHICAL LTD.Inventors: Amir Sagi, Assaf Shechter, Galit Shaltiel-Gold, Michal Daniely, Oren Meiron
-
Patent number: 10064891Abstract: An assembly of micelle aggregates, wherein each aggregate comprises micelles of an anionic surfactant and nano-sized particles of metallic silver. A product comprising such assemblies for use in treating or preventing bacterial infections.Type: GrantFiled: January 24, 2014Date of Patent: September 4, 2018Assignee: OTAGO INNOVATION LIMITEDInventors: Carla Joy Meledandri, Donald Royden Schwass
-
Patent number: 10064892Abstract: The invention relates to a method for producing an osteoinductive calcium phosphate material, the method comprising the steps of providing a sintered calcium phosphate starting material having a surface topography consisting of calcium phosphate grains, subjecting the sintered calcium phosphate starting material to a hydrothermal treatment of between 125-150° C. for a duration sufficient to change calcium phosphate grains on the surface of the starting material into calcium phosphate needles.Type: GrantFiled: July 18, 2014Date of Patent: September 4, 2018Assignee: KUROS BIOSCIENCES B.V.Inventors: Florence De Groot-Barrere, Vincent Van Miegem, Huipin Yuan, Joost De Bruijn
-
Patent number: 10064893Abstract: Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.Type: GrantFiled: July 6, 2015Date of Patent: September 4, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Christopher H. Contag, Stephen H. Thorne
-
Patent number: 10064894Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinations preparations for use in tissue regeneration and bone regeneration and pain reduction.Type: GrantFiled: October 30, 2017Date of Patent: September 4, 2018Assignee: RegenLab USA LLCInventors: Antoine Turzi, Donald Francois Du Toit
-
Patent number: 10064895Abstract: The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least: a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons, a whey isolate and/or a concentrate, and calcium caseinate.Type: GrantFiled: November 17, 2016Date of Patent: September 4, 2018Assignee: International Nutrition Research CompanyInventor: Claude Vincent
-
Patent number: 10064896Abstract: The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material (6) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material (10) that is dry and can be stored at room temperature for long periods of time. This powder (10) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture (20).Type: GrantFiled: July 17, 2014Date of Patent: September 4, 2018Assignee: Vivex Biomedical, Inc.Inventor: Harry Thomas Temple
-
Patent number: 10064897Abstract: Methods are also provided for isolating and using a whole-saliva leech extract in the treatment of a bacterial skin infection. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about ?20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant.Type: GrantFiled: February 7, 2017Date of Patent: September 4, 2018Assignee: Biopep Solutions, Inc.Inventors: Abbas Mohammad Ghawi, Ahmed Merzouk, Abdualrahman M. Abdualkader, Mohamed Alaama
-
Patent number: 10064898Abstract: This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.Type: GrantFiled: July 27, 2016Date of Patent: September 4, 2018Assignees: ADVAXIS, INC., UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: John Rothman, Anu Wallecha, Reshma Singh, Donald A. Harn, Jr., Yvonne Paterson
-
Patent number: 10064899Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: GrantFiled: April 11, 2018Date of Patent: September 4, 2018Assignee: CRESTOVO HOLDINGS LLCInventor: Thomas Julius Borody
-
Patent number: 10064900Abstract: Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore-forming bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject.Type: GrantFiled: February 4, 2014Date of Patent: September 4, 2018Assignee: Seres Therapeutics, Inc.Inventors: Geoffrey Von Maltzahn, Matthew R. Henn, David N. Cook, David Arthur Berry, Noubar B. Afeyan, Brian Goodman, Mary-Jane Lombardo McKenzie, Marin Vulic
-
Patent number: 10064901Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.Type: GrantFiled: December 19, 2017Date of Patent: September 4, 2018Assignee: Seres Therapeutics, Inc.Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
-
Patent number: 10064902Abstract: The invention relates to a novel strain of Bifidobacterium animals ssp. animalis, which is able, inter alia, to improve the function of the enteric nervous system, and to compositions said novel strain.Type: GrantFiled: December 10, 2013Date of Patent: September 4, 2018Assignee: COMPAGNIE GERVAIS DANONEInventors: Sophie Legrain-Raspaud, Gianfranco Grompone, Sandrine Capronnier, Tamara Smokvina, Marie-Christine Degivry, Biliana Lesic, Michel Neunlist
-
Patent number: 10064903Abstract: The Lactobacillus paracasei MCC1849 (NITE BP-01633) strain, which has a high IL-12 production-promoting action, is used as an ingredient of a drug, food or drink, or feed used for promotion of IL-12 production, immunostimulation, antivirus, or the like.Type: GrantFiled: September 9, 2016Date of Patent: September 4, 2018Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Tomohiro Tanaka, Noriyuki Iwabuchi, Yohei Sato, Kanetada Shimizu, Toshitaka Odamaki
-
Patent number: 10064904Abstract: Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.Type: GrantFiled: January 30, 2018Date of Patent: September 4, 2018Assignee: Vedanta Biosciences, Inc.Inventors: Jessica Schneider, Yun-Gi Kim, Bernat Olle, Shilpa Reddy, Jason Norman, Juan Patarroyo
-
Patent number: 10064905Abstract: Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.Type: GrantFiled: November 11, 2014Date of Patent: September 4, 2018Assignee: Ilysm, LLCInventor: Dennis M. Jenn
-
Method of preparing fermented crude extract having angiotensin converting enzyme inhibiting activity
Patent number: 10064906Abstract: This invention is related to a method of preparing a fermented crude extract having angiotensin converting enzyme inhibiting activity. The method comprises the following steps. A material is dried, milled, and then mixed with water in a weight ratio of 1:11 to form a mixture solution. 0.1 vol % ?-amylase is used to perform hydrolysis at 95° C. for 1 hour. 0.1 vol % glucoamylase is used to perform hydrolysis at 65° C. for 4 hours. A lactic acid bacterium is added in a culture medium containing the mixture solution to perform fermentation for 24 hours. The culture medium is centrifuged to take the supernatant thereof, and the supernatant is boiled for 20 minutes. The supernatant is filtered to obtain a fermented crude extract having angiotensin converting enzyme inhibiting activity.Type: GrantFiled: December 31, 2015Date of Patent: September 4, 2018Assignee: Chia Nan University of Pharmacy & ScienceInventors: Shu-Chen Wang, Pin-Der Duh, Shih-Ying Chen, Chen-Kai Chang, Jung-Tsai Chen, Chih-Kuang Chiu -
Patent number: 10064907Abstract: This invention relates to a process to improve the feed efficiency and carcass characteristics of (1) animals that are not showing clinical signs of disease or other microbial challenge and (2) animals that are not expected to show clinical signs of disease or other microbial challenge (that is, within the next 1-2 weeks or less) because of known management practices, such as weaning of piglets. The process of this invention can be used to decrease the cost of animal diets, to improve performance of animals and to improve the percentage of carcass in animals.Type: GrantFiled: August 19, 2015Date of Patent: September 4, 2018Assignee: Oligo Basics Agroindustrial LTDA.Inventor: Joan Torrent Campmany
-
Patent number: 10064908Abstract: The present invention provides a method for preventing, alleviating or treating a liver disease, comprising administering a composition comprising a Triticum aestivum Lamarck leaf extract or a fraction thereof to a subject in need thereof. Therefore, the method for preventing, alleviating or treating a liver disease of the present invention can improve the morphological change of liver tissue due to liver injury, inhibit apoptosis of hepatocytes, increase the synthesis of antioxidant enzymes such as glutathione (GSH) and superoxide dismutase (SOD) which can reduce oxidative stress in liver tissue, and reduce the levels of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) which are known to change sensitively in liver diseases.Type: GrantFiled: March 2, 2017Date of Patent: September 4, 2018Assignee: Wonkwang University Center for Industry-Academy CooperationInventors: Young Mi Lee, Dae Ki Kim, Hyeon Hui Ki, Hoon Yeon Lee
-
Patent number: 10064909Abstract: Provided herein is a method of binding growth hormone secretagogue receptors in one or more companion animals or livestock to stimulate hunger independent of release of growth hormone. The method can provide administering a therapeutically effective amount of a capromorelin-containing composition to a companion animal or livestock in need thereof for a period of at least 30 days. Optionally, one or more flavoring agents or flavor-masking agents can be added to the capromorelin-containing composition to enhance or mask the flavoring of the composition for the companion animal or livestock.Type: GrantFiled: May 22, 2017Date of Patent: September 4, 2018Assignee: ARATANA THERAPEUTICS, INCInventors: Linda Rhodes, Marie-Paul Lachaud, Bill Zollers, Ernst Heinen
-
Patent number: 10064910Abstract: The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment invoices administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g. by administration of tPA). Administration a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.Type: GrantFiled: June 23, 2012Date of Patent: September 4, 2018Assignee: NoNO Inc.Inventor: Michael Tymianski
-
Patent number: 10064911Abstract: The present invention relates to peptides for inhibiting angiogenesis. The present invention also relates to methods of inhibiting angiogenesis and methods of treating disorders associated with VEGF-induced vascular permeability using the peptides of the invention.Type: GrantFiled: May 22, 2017Date of Patent: September 4, 2018Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Yulia A. Komarova, Mark Rosenblatt, Asrar B. Malik
-
Patent number: 10064912Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in in vivo and in vitro environments).Type: GrantFiled: November 29, 2016Date of Patent: September 4, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Karl Deisseroth, Ofer Yizhar, Lisa Gunaydin, Peter Hegemann, Andre Berndt
-
Patent number: 10064913Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: March 15, 2011Date of Patent: September 4, 2018Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Jens Fritsche, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 10064914Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.Type: GrantFiled: May 4, 2016Date of Patent: September 4, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Pinchas Cohen, Changhan Lee